Clinical Trials on Hypocomplementemic Urticarial Vasculitis in Russian Federation

Total 29 results

National Medical Research Center for Therapy and...

Completed

Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

Endovenous Laser Ablation | Superficial Vein Thrombosis

Russian Federation
Central Clinical Hospital w/Outpatient Health Center...

Unknown

Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia

Diabetic Angiopathies | Peripheral Arterial Disease | Critical Limb Ischemia | Thromboangiitis Obliterans | Arteriosclerosis Obliterans

Russian Federation
AO GENERIUM

Completed

Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers

Hereditary Angioedema

Russian Federation
AO GENERIUM

Withdrawn

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

Hereditary Angioedema

Russian Federation
Novartis Pharmaceuticals

Completed

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria

Taiwan, Turkey, Belgium, Spain, Germany, India, Argentina, Canada, Russian Federation, Hungary
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines (PEARL-PROVOKE)

Chronic Inducible Urticaria

Taiwan, Turkey, United States, Australia, Hungary, Spain, Greece, Russian Federation, Slovakia
Novartis Pharmaceuticals

Completed

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Chronic Spontaneous Urticaria

United States, Spain, Germany, Taiwan, Japan, Australia, Russian Federation, Greece, Canada, United Kingdom
Novartis Pharmaceuticals

Completed

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Chronic Spontaneous Urticaria

United States, Spain, United Kingdom, Germany, Taiwan, Japan, Australia, Greece, Russian Federation, Canada
Sanofi

Completed

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)

Chronic Spontaneous Urticaria

Chile, Taiwan, Argentina, Germany, Canada, Russian Federation, Netherlands, Korea, Republic of, Spain, Greece, Italy, Japan, Poland
Novartis Pharmaceuticals

Completed

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Germany, Hungary, Spain, France, Turkey, Canada, Czechia, Netherlands, Poland, Japan, Russian Federation, Argentina, Denmark, Slovakia
Novartis Pharmaceuticals

Completed

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Hungary, Spain, France, Turkey, Canada, Czechia, Russian Federation, Poland, Japan, Argentina, Denmark, Slovakia
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

Belimumab in Remission of VASculitis (BREVAS)

Vasculitis

United States, Australia, France, Spain, Italy, Peru, Belgium, Canada, Germany, Romania, Mexico, United Kingdom, Hungary, Ireland, Poland, Switzerland, Czechia, Russian Federation, Norway, Sweden
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)

Chronic Spontaneous Urticaria

United States, Hungary, Taiwan, Spain, Italy, Korea, Republic of, Australia, France, Bulgaria, Czechia, Turkey, India, Argentina, Mexico, Japan, Colombia, Russian Federation, Puerto Rico, Singapore
InflaRx GmbH

Completed

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. (IXchange)

Granulomatosis With Polyangiitis (GPA) | Microscopic Polyangiitis (MPA)

Germany, Russian Federation, Belgium, France, Spain, Czechia, Italy, Netherlands, Sweden, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Chronic Spontaneous Urticaria

China, France, Spain, Argentina, Germany, Japan, United States, Canada, Hungary, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

Chronic Spontaneous Urticaria

United States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
Novartis Pharmaceuticals

Completed

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Chronic Spontaneous Urticaria

United States, Poland, Spain, Belgium, Germany, Russian Federation, Taiwan, Netherlands, Italy, Australia, France, Israel, Lebanon, Slovakia, India, Japan, Estonia, Philippines, Mexico, Argentina, United Kingdom, Vietnam, Brazil, Romania and more
Novartis Pharmaceuticals

Completed

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Chronic Spontaneous Urticaria

United States, Croatia, Hungary, India, Malaysia, Spain, Germany, Austria, Czechia, Denmark, France, Korea, Republic of, Greece, Singapore, Thailand, Bulgaria, Argentina, Turkey, Guatemala, Brazil, Russian Federation, Peru, Canada, Sw... and more
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, China, Hungary, Czechia, Turkey, Argentina, Colombia, Italy, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Chronic Spontaneous Urticaria

United States, Spain, Belgium, Croatia, Germany, Hungary, India, Malaysia, Russian Federation, Taiwan, Turkey, Netherlands, Italy, Australia, Israel, Korea, Republic of, Lebanon, Greece, Singapore, Slovakia, Thailand, Austria, Bulgaria and more
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Giant Cell Arteritis

Argentina, Estonia, France, United States, Australia, Belgium, Canada, Croatia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Polymyalgia Rheumatica

Argentina, Estonia, France, Japan, United States, Australia, Belgium, Canada, Germany, Hungary, Israel, Italy, Netherlands, Russian Federation, Switzerland, United Kingdom, Spain
University of Oxford
American College of Rheumatology; The European League Against Rheumatism (EULAR) and other collaborators

Unknown

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS)

Giant Cell Arteritis | Wegener's Granulomatosis | Microscopic Polyangiitis | Polyarteritis Nodosa | Takayasu Arteritis | Churg Strauss Syndrome

Korea, Republic of, United States, Germany, Australia, Japan, Ireland, Belgium, Italy, Denmark, Slovenia, Switzerland, Canada, Argentina, Austria, China, Czech Republic, Egypt, Finland, France, Hungary, India, Mexico, Netherlands, New... and more
GlaxoSmithKline

Completed

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Thrombosis, Venous

Netherlands, Spain, Germany, Italy, Poland, Russian Federation, France, Israel, Estonia, Hungary, Slovakia, Latvia, Greece, Ukraine, Czech Republic, Switzerland, Bulgaria
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

United States, Israel, Spain, Turkey, France, Hungary, Belgium, Germany, Argentina, Chile, Greece, Portugal, Bulgaria, Italy, Switzerland, Australia, Czechia, Denmark, Austria, Brazil, Guatemala, United Kingdom, Finland, Russian Federation and more
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
CSL Behring

Completed

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

Bulgaria, United States, Poland, Spain, Hungary, United Kingdom, Russian Federation, Macedonia, The Former Yugoslav Republic of, Argentina, Australia, Canada, Czech Republic, Israel, Romania, Sweden
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
Shire

Completed

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Hereditary Angioedema

United States, Australia, Israel, Canada, Hungary, Romania, Russian Federation, South Africa, Ukraine

Clinical Trials on Hypocomplementemic Urticarial Vasculitis in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations